+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy



Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy



Journal of Clinical Oncology 12(6): 1212-1216



To evaluate survival and neurodevelopmental outcomes following radiation therapy in infants and young children with residual or progressive medulloblastoma after primary chemotherapy. Thirteen young patients (< or = 36 months old) with medulloblastoma were treated with preirradiation multiagent chemotherapy and maximal surgical resection. Patients were scheduled to receive radiation therapy at the time of documented disease progression or upon completion of chemotherapy with residual disease. All patients underwent neurodevelopmental evaluation at the time of diagnosis, before receiving radiation therapy, and at yearly intervals posttreatment. Two patients completed the scheduled chemotherapy with residual disease and received delayed radiation therapy. The remaining 11 patients had either local or leptomeningeal progression during chemotherapy (median time to progression, 5 months). Six patients had a complete response (CR) to radiation therapy, and three of these children are alive 48 to 104 months postdiagnosis. Of the five patients who had progressive disease (PD) during radiation therapy or residual imaging abnormalities after treatment, only one is alive (with stable enhancing leptomeningeal abnormalities) 48 months postirradiation. Two additional survivors were rendered disease-free by surgical resection before radiation therapy and are without evidence of disease at 91 and 107 months after diagnosis. Thus, six of 13 patients are alive at 48 to 107 months postdiagnosis. Neurodevelopmental scores tended to be below age norms at diagnosis; scores improved during chemotherapy, but then decreased during posttreatment follow-up evaluation. Radiation therapy appears to produce long-term disease-free survival in a proportion of very young patients who have progressive or residual medulloblastoma during or after primary chemotherapy. However, neurodevelopmental deficits are frequent among long-term survivors.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 068676324

Download citation: RISBibTeXText

PMID: 8201384

DOI: 10.1200/jco.1994.12.6.1212


Related references

Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. Strahlentherapie und Onkologie 171(4): 247-248, 1995

Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. Journal of Clinical Oncology 12(6): 1212-1216, 1994

A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. International Journal of Radiation Oncology, Biology, Physics 60(2): 531-536, 2004

Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology 17(4): 548-555, 2003

Results of a pilot study of very low dose craniospinal irradiation plus chemotherapy for children under five with medulloblastoma An update. International Journal of Radiation Oncology Biology Physics 30(Suppl. 1): 170, 1994

Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer Journal 10(6): 386-390, 2004

Feasibility and outcome of patients with medulloblastoma treated with pre-irradiation chemotherapy and reduced dose craniospinal radiotherapy (csrh) using mycc as a molecular marker for prognosis. Journal of Clinical Oncology 26(15_Suppl): 10040-10040, 2016

Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study. Journal of BUON 18(2): 425-429, 2013

Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. International Journal of Radiation Oncology Biology Physics 42(5): 959-967, 1998

Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). International Journal of Radiation Oncology Biology Physics 34(4): 899-904, 1996

Role of amifostine as a cytoprotectant in children ≥ 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP)-based high dose chemotherapy. Journal of Clinical Oncology 24(18_Suppl): 9063-9063, 2016

Results of COG ACNS0331: A Phase III Trial of Involved-Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with Chemotherapy in Average-Risk Medulloblastoma: A Report from the Children's Oncology Group. International Journal of Radiation Oncology*biology*physics 96(5): 937-938, 2016

SIOP CNS GCT 96 final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for pat. 2013

EP-1127: Combined chemotherapy and craniospinal irradiation of adults medulloblastoma and PNET tumors. RadioTherapy and Oncology 119: S540-S541, 2016

Outcome and toxicity using helical tomotherapy for craniospinal irradiation in pediatric medulloblastoma. Clinical and Translational Oncology 16(1): 96, 2014